Physician profile
Jacqueline E Baumgartner
NPI 1518239581
$11,056.06
in general payments reported to CMS, 2019-2025
26 companies · $2,449 in 2025
The $2,449 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,628 · 2022: $2,333 · 2023: $2,321 · 2024: $2,325 · 2025: $2,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,710 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,709.89 |
| Education | $385.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,242.64 | 2021-2025 | |
| Janssen Biotech, INC. | $1,308.27 | 2021-2025 | Tremfya, Stelara, Remicade |
| Amgen INC. | $1,142.63 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $998.68 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $670.87 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $564.13 | 2021-2025 | Cabtreo, Jublia, Duobrii |
| Lilly USA, LLC | $501.62 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $497.18 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $455.63 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $388.67 | 2021-2025 | |
| Ucb, INC. | $374.92 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $351.43 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $292.06 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $283.72 | 2023-2025 | Zoryve |
| Genzyme Corporation | $253.03 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $250.60 | 2021-2024 | Dupixent, Libtayo |
| Organon LLC | $102.94 | 2025 | Vtama |
| Dermavant Sciences, INC. | $90.16 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $69.12 | 2021 | |
| Biofrontera INC. | $51.27 | 2021-2022 | |
| Epi Health, LLC | $46.97 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.02 | 2023 | Spevigo, Cyltezo |
| Vyne Pharmaceuticals INC. | $25.83 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.48 | 2025 | Ycanth |
| Journey Medical Corporation | $16.95 | 2025 | |
| Almirall LLC | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Baumgartner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.